deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT02523469

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer

Sponsor: Altor BioScience

Conditions Non-small Cell Lung Cancer
Interventions ALT-803 Nivolumab
Updated 23 times since 2017 Last updated: Jan 28, 2026 Started: Jan 8, 2016 Primary completion: Feb 24, 2023 Completion: Feb 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Altor BioScience and has accumulated 23 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshot~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~May 2020 · 4 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Jan 2022 · 11 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Apr 2023 · 3 months · monthly snapshot~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2026 · 17 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

23 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2024 — Feb 2026 [monthly]

    Completed PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  5. Jan 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

▶ Show 18 earlier versions

  1. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. May 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Feb 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. May 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Jan 2020 — May 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Aug 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jun 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Jul 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  15. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  16. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  17. Feb 2017 — Sep 2017 [monthly]

    Recruiting PHASE1_PHASE2

  18. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Jan 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Altor BioScience
  • Medical University of South Carolina
Data source: Medical University of South Carolina

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations